TI-22-013: Medication-Assisted Treatment – Prescription Drug and Opioid Addiction
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Substance Abuse and Mental Health Services Adminis notices from 2022.
Substance Abuse and Mental Health Services Adminis offered grants of up to $750,000 to the applicants described in the notice. It expected to make about 30 awards worth $22.6 million in total. Applications closed on April 29, 2022.
From the official notice on Grants.gov, last changed February 28, 2022. Checked November 7, 2026.
- Award ceiling$750,000
- Total funding$22.6 million
- Expected awards30
- Cost sharingNot required
- Funding typeGrant
Other notices with this title
Key dates
| Posted | February 28, 2022 |
|---|---|
| Deadline | April 29, 2022 |
| Archived by Grants.gov | May 29, 2022 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligible applicants are domestic public and private non-profit entities.
Is this a realistic fit?
- Past Substance Abuse and Mental Health Services Projects of Regional and National Significance awards averaged $2.3 million; this notice allows up to $750,000 per award.
- Most of the program's money (55% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
The purpose of this program is to provide resource to help expand/enhance access to Medications for Opioid Use Disorder (MOUD). It is expected that this program will help to 1) increase the number of individuals with Opioid Use Disorder (OUD) receiving MOUD; and 2) decrease illicit opioid use and prescription opioid misuse.
Who has won Substance Abuse and Mental Health Services Projects of Regional and National Significance grants before
From fiscal 2021 to 2025, Substance Abuse and Mental Health Services Projects of Regional and National Significance (93.243) awarded $13 billion across 5,689 grant awards, an average of $2.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Mental Health Association of New York City, Inc. | New York | 8 | $1.1 billion |
| California Department of Health Care Services | California | 6 | $502 million |
| Florida Department of Children and Families | Florida | 5 | $427 million |
| Ohio Department Mental Health | Ohio | 11 | $376 million |
| Pennsylvania Department of Drug and Alcohol Programs | Pennsylvania | 3 | $268 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is TI-22-013 still open?
No. It closed on April 29, 2022.
Who can apply for Medication-Assisted Treatment – Prescription Drug and Opioid Addiction?
Substance Abuse and Mental Health Services Adminis accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Medication-Assisted Treatment – Prescription Drug and Opioid Addiction?
Closed April 29, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $750,000 each. About $22.6 million in total across about 30 awards.
Who has won Substance Abuse and Mental Health Services Projects of Regional and National Significance grants before?
The largest recipients over five fiscal years were The Mental Health Association of New York City, Inc., California Department of Health Care Services, Florida Department of Children and Families. The program made 5,689 awards worth $13 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)